TY - JOUR
T1 - Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease
AU - Kaye, Jeffrey A.
AU - May, Conrad
AU - Atack, John R.
AU - Daly, Eileen
AU - Sweeney, Daniel L.
AU - Flint Beal, M.
AU - Kaufman, Seymour
AU - Milstien, Sheldon
AU - Friedland, Robert P.
AU - Rapoport, Stanley I.
PY - 1988/11
Y1 - 1988/11
N2 - Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin‐like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age‐matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterin were significantly Decemberreased. 5‐Hydroxyindole‐acetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower than in control subjects. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results, suggest that DAT patients with myoclonus represent a distinct clinical and neurochemical DAT subtype.
AB - Monoamine metabolites, biopterin, acetylcholinesterase (AChE) activity, and somatostatin‐like immunoreactivity (SLI) were determined in the lumbar cerebrospinal fluid (CSF) of 24 patients with dementia of the Alzheimer type (DAT) without myoclonus or extrapyramidal signs, in 8 patients with DAT and myoclonus, and in 14 age‐matched healthy control subjects. In patients with DAT with myoclonus as compared with both DAT patients without myoclonus and control subjects, the concentrations of homovanillic acid and biopterin were significantly Decemberreased. 5‐Hydroxyindole‐acetic acid was significantly lower in patients with myoclonic DAT as compared to patients with nonmyoclonic DAT, but not significantly lower than in control subjects. CSF AChE and SLI were significantly reduced in patients with DAT with or without myoclonus, as compared with control subjects, but AChE and SLI were not significantly different between dementia groups. These results, suggest that DAT patients with myoclonus represent a distinct clinical and neurochemical DAT subtype.
UR - http://www.scopus.com/inward/record.url?scp=0023769962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023769962&partnerID=8YFLogxK
U2 - 10.1002/ana.410240509
DO - 10.1002/ana.410240509
M3 - Article
C2 - 2462403
AN - SCOPUS:0023769962
SN - 0364-5134
VL - 24
SP - 647
EP - 650
JO - Annals of Neurology
JF - Annals of Neurology
IS - 5
ER -